GLP-1 & Incretin Science

Comparing Things That Were Never Compared

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

A network meta-analysis compares treatments that were never tested against each other by linking them through comparators they share, usually placebo. It produces indirect estimates, and rests on the assumption that the trials being linked are similar enough to connect.

Key facts

Purpose
Compare without a head-to-head
Method
Link trials through shared comparators
Key assumption
Transitivity (trials are comparable)
Threatened by
Differing populations, durations, endpoints
Weaker than
A direct randomised comparison
Stronger than
Informal cross-trial comparison

The problem it solves

Most treatments are never tested directly against each other, because head-to-head trials are expensive and commercially risky. Yet the question of which works better is what prescribers and payers need answered. Network meta-analysis extracts an answer from trials that already exist rather than requiring a new one.

How the linking works

If A was tested against placebo and B was tested against placebo, the difference between A and B can be estimated through their shared comparator. Extend that across many treatments and comparators and you get a network (hence the name) in which most pairs are connected by some path even where no direct edge exists.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The assumption everything rests on

Transitivity: that the trials being linked are similar enough that the comparison means something. If the trials of A enrolled healthier participants, ran shorter, or measured a different endpoint than the trials of B, the indirect comparison inherits those differences and attributes them to the treatments.

Why it is nonetheless better than what people do informally

Reading two trial results side by side and concluding one drug beats another is an indirect comparison too, just an undisciplined one, with no adjustment and no acknowledgement of uncertainty. A network meta-analysis does the same thing explicitly, propagates uncertainty into the estimate, and can be examined for whether the assumption holds.

Where it sits in the hierarchy

Below a direct randomised head-to-head, which is why REDEFINE 4 comparing CagriSema against tirzepatide, and TRIUMPH-5 comparing retatrutide against tirzepatide, carry weight that no network analysis can substitute for. Above informal comparison. It is a legitimate method used where the better evidence does not exist.

How to read one critically

Look at what the network actually connects and how. A comparison resting on one small trial as its only bridge is fragile regardless of how much data sits elsewhere in the network. Look at whether populations and durations across the linked trials are really comparable, and whether the authors examined that rather than asserting it.

Quick reference

Head-to-headNetwork meta-analysisInformal comparison
Randomised between armsYesWithin trials onlyNo
Uncertainty propagatedYesYesNo
Assumption requiredMinimalTransitivityUnstated

Frequently asked questions

How can a network meta-analysis compare untested pairs?

By linking them through shared comparators. If both were tested against placebo, the difference can be estimated through that common arm.

What is transitivity?

The assumption that the trials being linked are similar enough for the comparison to mean something. Differing populations or durations undermine it.

Is it as good as a head-to-head?

No. It sits below a direct randomised comparison, though above the informal side-by-side reading people do without it.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.